Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection
After 3-8 weeks of therapy, maribavir resistance emerged earlier and more frequently than ganciclovir resistance but was usually treatable using alternative therapy. Clinical Trials Registration. NCT02927067 (AURORA).
Authors
- Robin Kimiko Avery (ORCID: https://orcid.org/0000-0001-7692-3619)
- Ginger M. Pocock
- Catherine Cordonnier
- Jo‐Anne H. Young (ORCID: https://orcid.org/0000-0003-4182-341X)
- Sunwen Chou
- Carlos Solano (ORCID: https://orcid.org/0000-0003-3702-0817)
- Rafael F. Duarte (ORCID: https://orcid.org/0000-0002-5240-9815)
- Genovefa A. Papanicolaou (ORCID: https://orcid.org/0000-0002-2891-079X)
- Joan Gu
- Drew J. Winston
- Shariq Haider (ORCID: https://orcid.org/0000-0002-3776-5926)
- Johan Maertens
- Karl S. Peggs
Institutions
- University of Minnesota (US)
- Memorial Sloan Kettering Cancer Center (US)
- University College London Hospitals NHS Foundation Trust (GB)
- Johns Hopkins University (US)
- Universitat de València (ES)
- University of California, Los Angeles (US)
- Oregon Health & Science University (US)
- Université Paris-Est Créteil (FR)
- Juravinski Hospital (CA)
- Hospital Clínico Universitario de Valencia (ES)
- Los Angeles Medical Center (US)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Hôpitaux Universitaires Henri-Mondor (FR)
- University of Minnesota Medical Center (US)
- Takeda (United States) (US)
- VA Portland Health Care System (US)
- University College London (GB)
- Hamilton Health Sciences (CA)
- KU Leuven (BE)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2024-09-20
- DOI
- https://doi.org/10.1093/infdis/jiae469
- Citations
- 22
- Primary Topic
- Cytomegalovirus and herpesvirus research
- Type
- article
- Field-Weighted Citation Impact
- 8.51